07:00 , Aug 13, 2012 |  BioCentury  |  Strategy

Spinning Out mGluRs

Although Merck Serono S.A. decided to drop Parkinson's disease from its neuroscience portfolio, its preclinical compounds targeting metabotropic glutamate receptors for PD will continue to live on in a newco called Prexton Therapeutics S.A. Backed by...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Addex preclinical data

In a rat model of PD, 3 and 10 mg/kg ADX88178 significantly reduced time of catalepsy induced by haloperidol, a generic antipsychotic, vs. vehicle-treated controls (p<0.05). High-dose ADX88178 led to a reduction in catalepsy time...